RecruitingPhase 2NCT07400952
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Sponsor
Glaukos Corporation
Enrollment
100 participants
Start Date
Dec 23, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria2
- Be ≥ 18 and ≤ 55 years of age
- Diagnosis of keratoconus in the study eye
Exclusion Criteria2
- Pregnant, lactating or planning a pregnancy
- Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGGLK-221 Ophthalmic Solution
GLK-221 Ophthalmic Solution administered twice daily to both eyes
DRUGPlacebo Ophthalmic Solution
Placebo Ophthalmic Solution administered twice daily to both eyes
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07400952
Related Trials
The Homburg Keratoconus Center (HKC)
NCT039231011 location
Intacs Prescription Inserts for Keratoconus Patients
NCT021386691 location
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
NCT0712491012 locations
Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
NCT0713516712 locations
PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus
NCT073729111 location